May 18, 2013
Asthmapolis is the kind of company we hope, and expect, to see more of in the future. They combine a straightforward device (a sensor that sits on top of asthma inhalers) and a smartphone app, to achieve better results for patients and improve public health. By connecting previously unconnected data point and aggregating them, Asthmapolis can be successful as a company, reward its shareholders, and simultaneously reduce public health costs through unique epidemiological data and, hopefully, fewer asthma attack emergency room visits.
As we reported in July, Asthmapolis recently received FDA clearance for their sensor-enhabled inhaler.